Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Neucardin in chronic systolic heart failure
ChiCTR2000030171Phase 3Recruiting
- Sponsor
- Fuwai Hospital
- Start
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of neucardin in heart failure with reduced ejection fraction (HFrEF), sponsored by Fuwai Hospital. Primary endpoint: 52-week all-cause mortality. Started Feb 2018; status: recruiting.
02
Drugs
neucardin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2000030171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030171.